IKT - Inhibikase Therapeutics GAAP EPS of -$1.11 misses by $0.19 revenue of $116.41M August, 14 2023 04:34 PM Inhibikase Therapeutics Inc. 2023-08-14 16:34:39 ET Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q2 GAAP EPS of -$1.11 misses by $0.19 . Revenue of $116.41M (+1677.3% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$1.11 misses by $0.19, revenue of $116.41M